evipedia.aidev
← Back

Dihexa for Cognitive Enhancement

Evidence Review created on 08/11/2026 using AI4L / Grok 4

Also known as: PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

Motivation

Dihexa is a laboratory-made small peptide-like compound derived from a natural brain fragment of the blood-pressure system. Researchers designed it to be taken by mouth, survive breakdown in the body, and reach the brain. Interest centers on its proposed ability to strengthen nerve-cell connections and support memory and learning in animals with induced cognitive impairment.

The compound was created at Washington State University and later inspired a related drug candidate that entered human Alzheimer’s trials. Animal work reported rescue of spatial memory after drug-induced amnesia and in aged rodents, with increased markers of new synaptic connections. Key mechanism papers from the original laboratory were later retracted for image integrity problems, and Dihexa itself has never completed a human trial. Community and clinic use for cognitive optimization therefore rests almost entirely on animal and laboratory data and anecdote.

This review examines Dihexa’s proposed mechanism, the quality and limits of the animal evidence for cognitive benefit, theoretical and practical risks (including the growth-pathway cancer concern), dosing patterns used outside trials, and how a related clinical compound performed in people—an evidence map for risk-aware adults interested in longevity-oriented cognitive tools.

Benefits - Risks - Protocol - Conclusion

High-level overviews and primary reports on Dihexa’s origin, mechanism claims, and evidence limits.

Fewer than five high-quality, non-duplicate sources met eligibility: priority experts (Patrick, Attia, Huberman, Kresser, Life Extension, Lifespan.io) had no dedicated Dihexa content, and only one item was kept from the Harding–Wright laboratory to avoid same-organization duplicates. The list prioritizes foundational characterization, integrity-aware synthesis, and independent preclinical work.

Grokipedia

  • Dihexa

    Structured overview of chemistry, proposed HGF/c-Met pharmacology, preclinical cognitive findings, half-life estimates, and oncogenic c-Met cautions.

Examine

No Examine.com article for Dihexa was found. Examine.com does not typically cover unapproved research peptides.

ConsumerLab

No ConsumerLab review for Dihexa was found. ConsumerLab does not typically cover unapproved research peptides.

Systematic Reviews

One PubMed systematic review of experimental angiotensin IV–related work includes Dihexa among studied analogs.

No human systematic review or meta-analysis of Dihexa exists. No systematic review dedicated solely to Dihexa adverse effects was found on PubMed as of 11 August 2026.

Mechanism of Action

Dihexa is an oligopeptide analog of angiotensin IV (a short fragment of the renin–angiotensin system, the hormonal cascade that regulates blood pressure and also acts in the brain). Chemical end-capping was designed to raise metabolic stability, oral availability, and blood–brain barrier penetration relative to native angiotensin IV.

The leading proposed mechanism is high-affinity binding to hepatocyte growth factor (HGF) with potentiation of signaling through the HGF receptor c-Met (cellular mesenchymal-epithelial transition factor, a receptor tyrosine kinase). Downstream routes often cited include PI3K/AKT (phosphoinositide 3-kinase / protein kinase B) and MAPK/ERK (mitogen-activated protein kinase / extracellular signal-regulated kinase) pathways linked to spinogenesis, synaptogenesis, survival, and lower inflammatory cytokines in models. Competing accounts emphasize the older AT4 (angiotensin IV receptor subtype) / IRAP (insulin-regulated aminopeptidase) framing; whether effects fully reduce to HGF/c-Met remains debated, and two core HGF-mechanism papers from the original lab were retracted in 2025 after image-integrity findings.

Pharmacologically, Dihexa is described as orally active and brain-penetrant in rodents. In vitro rat serum stability half-life near 335 minutes has been reported; circulating half-life estimates in animals vary and are not established in humans. Selectivity beyond the proposed HGF/c-Met axis is not established. Human CYP (cytochrome P450) metabolism, protein binding, tissue distribution, and clearance remain uncharacterized in clinical pharmacokinetic studies. Related candidate fosgonimeton (ATH-1017) is a positive HGF/MET modulator for dementia and the main human HGF-pathway pharmacology in this family.

Historical Context & Evolution

Interest in angiotensin IV (Ang IV) as a cognitive peptide grew in the 1990s–2000s from rodent work showing learning and memory facilitation when Ang IV–related peptides were delivered into the brain. Native peptides were metabolically fragile and poorly suited to oral or systemic use.

At Washington State University (WSU), Joseph Harding, John Wright, and colleagues chemically stabilized Ang IV motifs as Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide). McCoy and colleagues (2013) reported oral and parenteral reversal of scopolamine-induced spatial deficits and activity in aged rats, with marked spinogenesis in culture. Later papers linked effects to HGF/c-Met potentiation and positioned Dihexa for Alzheimer’s and Parkinson’s models. Commercialization proceeded through M3 Biotechnology (later Athira Pharma)—companies founded or advised by members of that laboratory with a direct financial interest in HGF-pathway therapeutics—which advanced fosgonimeton (ATH-1017), a related HGF/MET positive modulator, into human trials rather than Dihexa itself.

In 2021, expressions of concern were issued for several WSU-group papers after image-manipulation questions. In 2025, foundational HGF-mechanism papers (including Benoist et al. 2014) were retracted after a university investigation. Athira’s late-stage Alzheimer’s program with fosgonimeton did not meet primary endpoints in LIFT-AD (2024–2025). In parallel, Dihexa entered research-chemical and longevity-clinic markets as an unapproved oral or compounded agent despite no Dihexa-specific human trials.

Expected Benefits

Low 🟩

Spatial memory rescue in cognitive-deficit animal models

In scopolamine-amnesia and aged-rat models, oral or parenteral Dihexa improved Morris water maze performance in original studies. Independent APP/PS1 (amyloid-precursor/presenilin transgenic) mouse work reported restored spatial learning and higher synaptic markers. These remain animal findings, not human outcomes, with integrity caveats on the original stream.

Magnitude: Morris water maze latency/errors restored to vehicle-control levels at about 0.5–2.0 mg/kg/day oral or parenteral in scopolamine and aged-rat models.

Synaptogenesis and spinogenesis (preclinical)

Cell-culture and hippocampal preparations treated with Dihexa at picomolar-to-nanomolar ranges showed increased dendritic spine density and synaptic marker colocalization, comparable to HGF in developer assays. The often-quoted “orders of magnitude more potent than BDNF (brain-derived neurotrophic factor)” claim refers to in-vitro spine assays only.

Magnitude: Roughly threefold spine-density increases reported in some culture conditions; not quantified as a human cognitive endpoint.

Neuroinflammation reduction in Alzheimer’s disease (AD)–model mice

Sun et al. (2021) reported lower glial activation, reduced IL-1β (interleukin-1 beta) and TNF-α (tumor necrosis factor-alpha), higher IL-10 (interleukin-10), and PI3K/AKT engagement after Dihexa in APP/PS1 mice. Durability outside that model is unproven.

Magnitude: Directional cytokine and histology changes in one transgenic mouse study; the literature report no outcome figure.

Speculative 🟨

Cognitive enhancement in healthy or mildly impaired humans

Clinic marketing and community reports describe clearer thinking, memory, and mood on oral or topical Dihexa. No randomized human trial of Dihexa has established efficacy for cognitive enhancement, mild cognitive impairment, or dementia.

Disease-modifying benefit in Alzheimer’s or Parkinson’s disease via Dihexa itself

Developer reviews hypothesized synaptic repair as disease modification. Human late-stage testing of the related HGF modulator fosgonimeton did not meet primary cognitive/functional endpoints, which weakens—but does not fully refute—extrapolation to Dihexa.

Benefit-Modifying Factors

  • Baseline cognitive status: Animal rescue is clearest in induced deficit or aged models; benefit magnitude in already high-performing young adults is unknown and may be smaller.

  • Baseline biomarkers: No validated blood or imaging biomarker predicts who will gain cognitive benefit from Dihexa; response cannot be pre-selected by routine labs.

  • Age: Aged-rat data are often cited; human age interactions for Dihexa are unstudied. Older adults also carry higher undiagnosed cancer prevalence, relevant to c-Met risk framing.

  • Sex: Published Dihexa rodent cognition work is heavily male-biased; sex-specific response data are lacking.

  • Genetic and pathway context: Variants affecting HGF/MET signaling, growth-factor biology, or cancer predisposition could theoretically alter benefit–risk balance; no Dihexa pharmacogenomic map exists.

  • Concomitant neurodegeneration or inflammation: Models with scopolamine, amyloid pathology, or LPS-type (lipopolysaccharide-triggered) inflammation show larger relative gains than intact animals; real-world translation is untested.

  • Product authenticity: Research-chemical purity variability can erase any theoretical benefit through underdosing or substitution.

Potential Risks & Side Effects

Medium 🟥 🟥

Uncharacterized human safety of Dihexa itself

Dihexa has no completed dedicated Phase 1–3 program. Acute and chronic human adverse-event rates, organ toxicity thresholds, drug–drug interaction liabilities, and reproductive risks are not established in peer-reviewed clinical datasets. Related HGF-pathway drug fosgonimeton was generally tolerable in trials, with discontinuations driven largely by injection-site reactions for the subcutaneous product—not a full surrogate for oral/research Dihexa.

Magnitude: Not quantified in available studies.

Low 🟥

Acute tolerability symptoms (anecdotal / clinic reports)

Community and clinic summaries list mild headache, fatigue, vivid dreams, irritability, gastrointestinal upset, and nasal irritation (intranasal use). These are uncontrolled observations, not trial-grade incidence rates.

Magnitude: Usually mild and early in uncontrolled clinic reports; the literature report no outcome figure.

Research-chemical quality and contamination risk

Unregulated powder and “research only” products may be misidentified, degraded, or contaminated. Without pharmaceutical manufacturing controls, dose and identity are uncertain.

Magnitude: Misidentification and contamination risk rises with anonymous online vendors; the literature report no outcome figure.

Speculative 🟨

Tumor promotion via sustained HGF/c-Met activation

c-Met is an oncogene pathway used by many solid tumors. Chronic potentiation raises a theoretical risk of promoting occult malignancy. Long-term Dihexa carcinogenesis studies are absent; the concern is mechanistic, not clinical.

Unknown developmental, cardiac, or off-target growth effects

HGF biology extends beyond the brain (liver regeneration, angiogenesis, cell motility). Off-target tissue effects under chronic use remain unmapped.

Risk-Modifying Factors

  • Personal or family cancer history: Prior malignancy or high hereditary cancer risk theoretically amplifies concern about c-Met stimulation.

  • Genetic polymorphisms: Variants in MET pathway or cancer-predisposition genes could theoretically alter proliferative risk; no Dihexa-specific pharmacogenomic map exists.

  • Baseline biomarkers: No validated blood or imaging marker predicts Dihexa-specific toxicity or c-Met-related risk; routine labs and age-appropriate cancer screening are proxies only.

  • Age: Cancer incidence rises with age; absolute risk context differs for younger versus older adults seeking cognitive optimization.

  • Sex: No robust sex-specific Dihexa safety data; baseline cancer spectra differ by sex.

  • Baseline inflammatory or proliferative disease: Active fibrotic, angiogenic, or neoplastic processes could interact with HGF biology.

  • Hepatic or metabolic impairment: Human clearance path is unknown; impaired metabolism could raise exposure unpredictably.

  • Product source: Non-pharmaceutical sources raise purity and dosing error risk independently of pharmacology.

Key Interactions & Contraindications

Documented, trial-grade interaction tables for Dihexa do not exist. The following are mechanism-based cautions and practice patterns, not labeled contraindications.

  • Growth-pathway oncology drugs (c-Met / HGF inhibitors such as capmatinib, tepotinib): Theoretical pharmacodynamic opposition; severity: caution — may blunt oncology therapy or Dihexa effect.

  • Proliferative biologic therapies and some growth-factor agents: Additive growth signaling possible; severity: caution — monitor if any legitimate co-use context exists.

  • Other experimental nootropic peptides (for example cerebrolysin, PE-22-28, high-dose growth hormone secretagogues): Overlapping plasticity claims without interaction data; severity: monitor — unknown synergy or adverse CNS (central nervous system) load.

  • Strong CYP (cytochrome P450) modulators (e.g., ketoconazole, rifampin, grapefruit juice): Human metabolic enzymes for Dihexa unestablished; severity: monitor — theoretical exposure shifts until PK (pharmacokinetics) are defined.

  • Anticholinergic cognitive burden (diphenhydramine, some bladder antispasmodics): Opposes the cognitive goal even if no direct PK clash; severity: caution — may mask or counteract intended benefit.

  • Supplements with pro-angiogenic or high-dose growth claims: Additive theoretical proliferative signaling; severity: monitor.

Populations who should avoid Dihexa:

  • Active cancer or recent malignancy (especially c-Met–driven tumors)
  • Undiagnosed suspicious masses pending workup
  • Pregnancy and breastfeeding (no reproductive toxicology package)
  • Children and adolescents
  • Anyone seeking an FDA (Food and Drug Administration)–approved, evidence-based dementia therapy (Dihexa is not one)

Risk Mitigation Strategies

  • Cancer screening before use: Age-appropriate screening reduces the chance of dosing over occult disease in a c-Met–active agent.

  • Time-limited cycles, not indefinite daily use: Common clinic pattern is weeks-on / weeks-off given long tissue-effect claims and missing chronic data.

  • Lowest practical exposure: Starting near the low end of reported mg ranges limits cumulative unknown-toxicity and theoretical c-Met load; no validated minimum effective human dose exists.

  • Pharmaceutical-grade or physician-compounded source only: Avoids anonymous research powders with unknown identity.

  • Single-agent start before stacks: Isolating one experimental neurotrophic at a time makes adverse effects easier to attribute if they appear.

  • Red-flag symptom pause: New focal neurologic symptoms, unexplained weight loss, or new masses are treated in clinic patterns as triggers for medical evaluation rather than dose escalation.

  • Not a substitute for proven dementia care: Practice patterns keep disease-modifying or symptomatic standard therapies intact when those are indicated.

Therapeutic Protocol

No regulator-approved human dose, schedule, or indication exists for Dihexa. The patterns below reflect preclinical conversion attempts and longevity-clinic / community practice, not a standard of care.

  • Evidence baseline: Rodent oral efficacy often cited near ~0.05–2 mg/kg in deficit models; simple allometric conversion is not a validated human regimen.

  • Community oral ranges: Frequently referenced ~5–20 mg once daily (sometimes up to ~30–40 mg in aggressive protocols); entirely unvalidated.

  • Routes: Oral capsules/powder, topical/transdermal, intranasal, and occasional subcutaneous research use appear in clinic marketing; comparative human bioavailability unknown.

  • Timing: Usually once daily; half-life claims in animals are long and inconsistent, so split dosing is not established as necessary.

  • Cycling: Common patterns include 4–8 weeks on and 2–4 weeks off, reflecting caution rather than efficacy data.

  • Sex and age: No dose adjustments validated; older users warrant stricter cancer-risk review.

  • Genetics / biomarkers: No MET-pathway or APOE-guided (apolipoprotein E gene variants linked to Alzheimer’s risk) dosing algorithm for Dihexa.

  • Baseline biomarkers: No validated pretreatment labs guide Dihexa dose or expected response; cognitive and metabolic baselines support monitoring, not titration.

  • Pre-existing conditions: Active cancer, pregnancy, or unstable systemic disease are avoidance contexts; no dose-adjustment algorithm exists for organ impairment.

  • Related clinical anchor: Fosgonimeton used fixed subcutaneous mg doses (for example 40 mg daily in LIFT-AD)—a different molecule and route, not a Dihexa label.

Discontinuation & Cycling

  • Duration intent: Not characterized as lifelong therapy; experimental and typically time-limited.

  • Withdrawal: No established physical dependence or classic withdrawal syndrome in published literature.

  • Tapering: Formal taper protocols are not defined; some practitioners step down over several days after high oral intakes out of caution.

  • Cycling rationale: Used to limit cumulative c-Met exposure and reassess subjective cognition off-drug.

  • Loss of effect: Any perceived benefit may fade after stopping; no rebound dementia signal is documented for Dihexa.

  • Rechallenge: Only after symptom and risk reassessment if experimental use continues.

Sourcing and Quality

  • Regulatory status: Not FDA-approved; sold as a research chemical or via compounding/longevity clinics in some jurisdictions.

  • Identity testing: Lots with third-party HPLC/MS (high-performance liquid chromatography / mass spectrometry) identity and purity certificates are stronger evidence of composition; COA (certificate of analysis) without batch match is weak assurance.

  • Formulation: Oral vs topical vehicles differ widely; absorption claims are rarely bioequivalence-tested.

  • Compounding pharmacies vs research vendors: Physician-supervised compounding generally offers better chain-of-custody than anonymous peptide marketplaces.

  • Storage: Peptide-stable conditions (cool, dry, light-protected) are the usual handling pattern; degraded product undermines any dose logic.

  • Legal access: Import and “research only” labeling may conflict with local drug laws; legality varies by country.

Practical Considerations

  • Time to effect: Animal rescue can appear within days of dosing around learning tasks; human anecdotal onset is often described over 1–4 weeks—uncontrolled.

  • Common pitfalls: Equating in-vitro “potency vs BDNF” with clinical strength; ignoring retractions; stacking multiple gray-market peptides; assuming Athira trial data equal Dihexa proof.

  • Regulatory reality: Unapproved for cognitive enhancement or dementia; marketing claims can outrun evidence.

  • Cost and access: Clinic programs and research vials vary widely in price; higher price does not certify purity or efficacy.

  • Expectation management: Related HGF-pathway Phase 2/3 testing did not meet primary endpoints—relevant context for optimism calibration.

Interaction with Foundational Habits

  • Sleep: Interaction direction: none established on architecture; vivid dreams are occasionally reported. Sleep remains the dominant driver of memory consolidation; experimental peptides do not replace it.

  • Nutrition: Interaction direction: none established (no food-effect study). Adequate protein and micronutrients support general synaptic health; no Dihexa-specific diet is validated.

  • Exercise: Interaction direction: potentially complementary (indirect), not proven synergistic. Aerobic and resistance training independently raise neurotrophic signaling, including BDNF pathways.

  • Stress management: Interaction direction: indirect via hippocampal plasticity. Reducing allostatic load (cumulative physiological wear from chronic stress) may matter more than an unproven peptide for cognition.

Monitoring Protocol & Defining Success

Before any experimental exposure, establish baseline cognition and rule out reversible causes of brain fog (sleep apnea, thyroid disease, B12 deficiency, depression, medication anticholinergic load). Ongoing monitoring is clinical and functional rather than Dihexa-specific, because no validated therapeutic drug-level or target-engagement assay is available for consumer use.

Suggested cadence if experimental use proceeds under clinician oversight: baseline; 2–4 weeks; end of each cycle; and prompt evaluation for red-flag symptoms. Success is defined against the individual’s pre-specified cognitive goals (for example stable occupational performance, validated digital cognitive scores), not marketing claims. Failure criteria include new systemic symptoms, suspected proliferative disease, or no meaningful subjective/objective change after a time-limited cycle.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Cognitive composite (e.g., MoCA or digital battery) Stable or improved vs personal baseline Tracks the intended endpoint MoCA (Montreal Cognitive Assessment) is a brief screen; formal neuropsychological testing if impairment suspected
hs-CRP Generally <1.0 mg/L for low systemic inflammation Flags inflammatory confounders of cognition hs-CRP = high-sensitivity C-reactive protein; not Dihexa-specific; morning non-acute illness draw
TSH, free T4 TSH roughly 0.5–2.5 mIU/L (functional aims vary) Thyroid dysfunction mimics cognitive decline TSH = thyroid-stimulating hormone; free T4 = free thyroxine; conventional lab ranges wider; interpret clinically
Vitamin B12 / methylmalonic acid B12 often targeted >400–500 pg/mL with normal MMA Deficiency causes reversible cognitive symptoms MMA (methylmalonic acid) clarifies functional B12 status
Fasting glucose / HbA1c Glucose ~70–90 mg/dL fasting; HbA1c often aimed <5.5% Metabolic health modulates brain aging HbA1c = glycated hemoglobin (average glucose over ~3 months); not a Dihexa drug level
Age-appropriate cancer screening Per guidelines (colon, breast, prostate, lung as indicated) Partially addresses theoretical c-Met risk Screening ≠ proof of safety on Dihexa
CBC / CMP Within lab reference; investigate new cytoses (abnormal rises in blood cell counts) or enzyme rises Basic organ safety net CBC = complete blood count; CMP = comprehensive metabolic panel; no Dihexa-specific hepatotoxicity signal established

Qualitative markers:

  • Working memory and recall in daily tasks
  • Attention stamina and mental fatigue
  • Mood stability and anxiety
  • Sleep quality and dream intensity
  • Headache, irritability, or GI (gastrointestinal) change after dose changes

Emerging Research

  • Fosgonimeton LIFT-AD outcome: Phase 2/3 NCT04488419 did not meet primary GST (Global Statistical Test) or key cognitive/functional endpoints; small non-significant trends and biomarker signals leave HGF modulation biologically interesting but unproven as AD therapy (Porsteinsson et al., 2025).

  • Fosgonimeton Phase 1 package: NCT03298672 supported short-term tolerability and electrophysiology signals of target engagement in a small AD subset (Hua et al., 2022).

  • Related program trials terminated: Alzheimer open-label extension NCT04886063 and SHAPE (NCT04831281; Parkinson disease dementia / dementia with Lewy bodies) were terminated—context for program trajectory.

  • Integrity remediation of the Dihexa literature: 2025 retractions of core HGF-mechanism papers require independent replication of spinogenesis and receptor claims before mechanism is treated as settled.

  • Independent preclinical extensions: Non-WSU groups continue disease-model work (for example APP/PS1 cognition; Huntington-like toxin models), which may clarify or limit generalization.

  • Human Dihexa PK/PD gap: No registered Dihexa (PNB-0408) interventional cognitive trial was identified on ClinicalTrials.gov as of this review; future first-in-human PK/PD (pharmacokinetics/pharmacodynamics) work would be decision-changing.

Conclusion

Dihexa is an experimental compound made from a natural blood-pressure-related brain peptide fragment, promoted for cognitive enhancement on animal memory rescue and laboratory tests of nerve-connection growth. The proposed story centers on boosting a natural growth signal (hepatocyte growth factor) through its cell-surface receptor (c-Met), with effects on nerve connections and inflammation in models. That story is incomplete: major supporting papers from the originating laboratory—whose members held commercial stakes via M3 Biotechnology and Athira Pharma—were retracted after image-manipulation problems, and Dihexa has not completed human benefit or long-term safety studies.

For a longevity-oriented, risk-aware adult, the evidence map is thin on confirmed human benefit and thicker on uncertainty. Plausible upsides remain limited to animal and laboratory findings—spatial memory rescue in impaired rodents and structural nerve-connection changes in lab cell studies. Principal cautions are unknown human safety, product-quality variability in research-chemical markets, and theoretical concern that chronic activation of a cancer-linked growth pathway could raise cancer risk. A related experimental drug on the same system did not clearly improve thinking or daily function in large Alzheimer studies—relevant context, not a direct verdict on Dihexa.

Overall evidence quality for human cognitive enhancement is low to speculative. Interest is understandable given the idea that it rebuilds nerve connections, but the intervention remains experimental. Any experimental use sits outside approved medical treatments and depends on risk tolerance, source quality, and medical oversight rather than proof.

Top - Benefits - Risks - Protocol